CLVS Clovis Oncology Inc.

5.6
+0.4  (+8%)
Previous Close 5.2
Open 5.46
Price To Book -10.18
Market Cap 306,076,618
Shares 54,656,539
Volume 5,799,644
Short Ratio
Av. Daily Volume 3,132,352

NewsSee all news

  1. AstraZeneca Success On Prostate Cancer Drug Lowers Enthusiasm For Clovis
  2. 3 Stocks That Are Absurdly Cheap Right Now
  3. Clovis Oncology Announces Pricing of $250 Million of Convertible Senior Notes
  4. Clovis Oncology to Offer $225 Million of Convertible Senior Notes
  5. Edited Transcript of CLVS earnings conference call or presentation 1-Aug-19 12:30pm GMT

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

sNDA filing due 4Q 2019.
Rubraca
BRCA-mutant advanced prostate cancer
Phase 3 trial planned.
Opdivo and Rubraca
Triple-negative breast cancers
Phase 3 enrolment has commenced - noted August 8, 2018.
Opdivo and Rubraca ATHENA
Ovarian Cancer - First-line maintenance treatment
Phase 3 trial open for enrollment - February 22, 2017.
Rucaparib - TRITON3
Castration-Resistant Prostate Cancer
Phase 1b/2 trial initiated January 2016
Rociletinib in combination with atezolizumab
EGFR-mutant non-small cell lung cancer
Approval announced April 6, 2018.
Rucaparib ARIEL3
Ovarian cancer patients with a BRCA-like mutation
PDUFA date was June 28, 2016. Company expect CRL. Phase 3 TIGER-3 also terminated.
Rociletinib
Mutant EGFR T790M-positive lung cancer
Development discontinued
Lucitanib
Breast cancer
Approved December 19, 2016. Original PDUFA date under priority review was February 23, 2017.
Rucaparib ARIEL2
Cancer - ovarian second line
Phase 2 updated data due at ESMO late-September, 2019.
Rucaparib - TRITON2
Castrate-resistant prostate cancer (mCRPC)
Phase 2 trial to be discontinued due to lack of efficacy - April 12, 2019.
Rucaparib - ATLAS
Urothelial carcinoma
ESMO presentation at ESMO October 2018.
Lucitanib
HR+ Her2- metastatic breast cancer
Phase 3 confirmatory trial is enrolling.
Rucaparib ARIEL4
Relapsed ovarian cancer patients with BRCA mutations
Phase 2 data presented at AACR April 2019. PFS 9.1 months.
Rucaparib
Platinum-sensitive pancreatic cancer
Phase 1b/2 trial enrolling.
Lucitanib with Opdivo
Solid tumors
Phase 1/2 trial underway.
Lucitanib with Rubraca (SEASTAR)
Ovarian cancer

Latest News

  1. AstraZeneca Success On Prostate Cancer Drug Lowers Enthusiasm For Clovis
  2. 3 Stocks That Are Absurdly Cheap Right Now
  3. Clovis Oncology Announces Pricing of $250 Million of Convertible Senior Notes
  4. Clovis Oncology to Offer $225 Million of Convertible Senior Notes
  5. Edited Transcript of CLVS earnings conference call or presentation 1-Aug-19 12:30pm GMT
  6. Clovis (CLVS) Q2 Earnings & Sales Lag Estimates, Shares Down
  7. Clovis Oncology (CLVS) Q2 2019 Earnings Call Transcript
  8. Here's Why Clovis Oncology Stock Fell as Much as 15.6% Today
  9. Will Clovis Oncology (CLVS) Report Negative Earnings Next Week? What You Should Know
  10. What's in the Cards for Zynerba (ZYNE) This Earnings Season?
  11. Clovis Oncology to Announce Second Quarter 2019 Financial Results and Host Webcast Conference Call on August 1
  12. Glaxo's Zejula Meets Goal in First-Line Ovarian Cancer Study
  13. Does Clovis Oncology, Inc. (NASDAQ:CLVS) Have A Particularly Volatile Share Price?
  14. Do Options Traders Know Something About Clovis (CLVS) Stock We Don't?
  15. Pfizer's Talzenna Gets Approval in Europe for Breast Cancer
  16. AstraZeneca/Merck's Lynparza Wins EU Nod for First-Line Use
  17. See what the IHS Markit Score report has to say about Clovis Oncology Inc.
  18. Is Clovis Oncology Inc (CLVS) A Good Stock To Buy?